
Newsletter
Promoter: | Pennybuster.com | Paying Party: | No Third Party |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
PSTI | No compensation | UNKNOWN |
Max Profit: 20.87 % | Gain at close: 12.17 % |

(Mailing list information, including unsubscription instructions, is located at the end of this message.)
Pluristem Therapeutics Inc. (Nasdaq: PSTI)
http://www.pluristem.com/
Company Information:
Matam Advanced Technology Park
Building #20
Haifa 31905, Israel
Tel : +972-74-710-7171
Fax : +972-74-710-7172
E-Mail: info@pluristem.com
CIK: 0001158780
Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases.
Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells require no tissue matching prior to administration, making them an “off-the-shelf” product.
The company’s GMP-certified in-house manufacturing facilities allow it to efficiently produce commercial quantities of homogeneous, clinical-grade PLX cells. Pluristem is currently the only company manufacturing large quantities of placenta-based cell products using a 3D bioreactor. Driving these development efforts is a management team dedicated to shaping the future of the company and of placenta-based cell therapies. The Pluristem team has many decades of industry and research experience and draws on this as it continues to progress towards company goals.
Management:
http://www.pluristem.com/index.php/about2/management.html
Clinical Program:
http://www.pluristem.com/index.php/clinic-program.html
Recent News and Press:
http://www.pluristem.com/index.php/press-room.html
http://finance.yahoo.com/q/h?s=PSTI+Headlines
http://seekingalpha.com/symbol/PSTI
Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK01158780&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
Transfer Agent:
Nevada Agency and Transfer Company
50 W. Liberty St.
Suite 880
Reno, NV 89501
Investor Relations: U.S.A.
Karine Kleinhaus, M.D., M.P.H.
Divisional VP, North-America
karinek@pluristem.com
PSTI Currently 1.06 Looks Ready 2 Roll Here!
Happy Trading!
:)
PSP
No Compensation. No Position.
The following information is a reminder of your current mailing list subscription:
You are subscribed to the following list:
pennystockprophecy.com
using the following email:
xxxxxx@gmail.com
You may automatically unsubscribe from this list at any time by visiting the following URL:
http://www.pennybuster.com/cgi-bin/dada/mail.cgi/u/pennyprophecy/
If the above URL is inoperable, make sure that you have copied the entire address. Some mail readers will wrap a long URL and thus break this automatic unsubscribe mechanism.
You may also change your subscription by visiting this list's main screen:
http://www.pennybuster.com/cgi-bin/dada/mail.cgi/list/pennyprophecy
If you're still having trouble, please contact the list owner at:
pennybuster@pennybuster.com
The following physical address is associated with this mailing list:
pennystockprophecy.com
Mailing List Powered by Dada Mail